With a vision to develop innovative off-the-shelf cellular therapies possessing wide applicability, AMASA is committed to improving quality of life and increasing progression free survival for all patients suffering from a variety of advanced cancers, starting with malignant brain tumor, glioblastoma.
AMASA has developed a unique “off-the-shelf” allogeneic cell surface receptor targeted engineered bi-functional stem cells that express the cell killing and immunomodulatory proteins and also the ability to release our propriety oncolytic viruses.
The Amasa platform has evolved to address the significant challenges that still exist in treating solid tumors
Amasa Therapeutics’ unparalleled approach addresses critical limitations in current cancer treatments and offers broad therapeutic potential across some of the most formidable malignancies, starting with high-grade Glioblastoma (GBM).
Our innovative strategy overcomes key challenges related to biodistribution, significantly enhances on-site retention of therapeutic cells, and enables targeted migration toward tumor tissues. These unique advantages position our platform as a transformative solution in solid tumor immunotherapy.
Building on compelling preclinical data, we are advancing toward a first-in-human clinical trial evaluating our hydrogel-encapsulated, engineered allogeneic cell product in patients with primary GBM, a devastating brain cancer with limited treatment options and poor prognosis.
Global donor cell banks provide immediate access to allogeneic, tumor-matched cells
Initial product from Amasa pipeline (AMA-020) addresses key challenges in patient care pathway
A new approach focused on engineering allogeneic cells and t-cell engagers to trigger immune system modulation